By [Your Name/Editorial Staff]
In the landscape of modern oncology, the gap between clinical research and the lived experience of patients is often wide. Bridging that chasm requires more than just medical breakthroughs; it requires a persistent, human-centric form of advocacy. Kelly Shanahan, M.D., President of METAvivor, a leading nonprofit organization dedicated to metastatic breast cancer (MBC) research and awareness, recently provided a poignant look at this work, balancing the professional rigors of high-level advocacy with the deeply personal reality of living with terminal illness.
The Intersection of Science and Community
For Dr. Shanahan, the month of June was defined by a whirlwind of activity that spanned both coasts, highlighting the multifaceted nature of her role. Her recent journey underscored the dual identity she maintains: that of a physician—trained to look for evidence-based outcomes—and that of a patient, navigating the emotional complexities of long-term MBC survival.
Her journey began in San Francisco, where she engaged in a series of high-level industry dialogues. Representing METAvivor at Genentech’s "Insight Exchange" and "Experience Exchange," Dr. Shanahan navigated a room filled with representatives from over 125 organizations. The breadth of these meetings—covering diseases ranging "literally from A to Z"—served as a reminder that while the pathologies of various diseases differ, the systemic challenges in patient advocacy, access to clinical trials, and funding remain universal.
A Chronology of Advocacy: From San Francisco to Philadelphia
The arc of Dr. Shanahan’s recent advocacy work serves as a microcosm for the broader movement within the cancer community.
- Days 1–3 (San Francisco): The focus was on structural change. By participating in Genentech’s forums, Dr. Shanahan contributed to the dialogue on how pharmaceutical innovation can be better aligned with the actual needs of the patient population. These "exchanges" are critical, as they allow patient advocates to provide the "real-world" context that clinical data often overlooks.
- Days 4–7 (Philadelphia): The setting shifted from the corporate boardrooms of Silicon Valley to the deeply personal atmosphere of the 20th Living Beyond Breast Cancer (LBBC) MBC conference. This transition marks the shift from macro-advocacy (policy and research) to micro-advocacy (community support and shared trauma).
For Dr. Shanahan, Philadelphia was more than a professional commitment; it was an emotional homecoming. "For me, the LBBC conference is the place to connect with our community, to give and get hugs, to laugh, to cry, to remember those who are no longer with us," she reflected.
Recognizing the "Changemakers"
A significant milestone during the Philadelphia conference was the recognition of two METAvivor board members, Dr. Shanahan and Janice Cowden, as "Changemakers." This honor, bestowed by Living Beyond Breast Cancer, is a testament to the tireless, often unpaid labor that characterizes the rare-disease and terminal-illness advocacy sectors.
The "Changemaker" designation acknowledges the pivotal role these individuals play in shifting the national conversation surrounding MBC. Historically, metastatic breast cancer has been underfunded and sidelined in favor of early-stage breast cancer research. Advocates like Shanahan and Cowden have spent years pushing for a paradigm shift—insisting that research dollars be allocated specifically to the metastatic form of the disease, which remains the primary cause of breast cancer-related mortality.
Implications: The Emotional Labor of Long-Term Survival
Perhaps the most challenging aspect of Dr. Shanahan’s trip was her participation in a panel titled, "The emotional impact of living long-term with MBC." As a physician, Dr. Shanahan is accustomed to an objective, "sciency" framework. Stepping into the realm of emotional vulnerability required a recalibration of her professional identity.
The implications of her participation are significant. In the medical community, the "patient-expert" is a rising phenomenon. By sharing her journey—including the grief of losing her career as an OB/GYN—Dr. Shanahan provided a framework for others to process their own losses. She noted that her involvement with METAvivor has served as a primary coping mechanism, providing a sense of agency in a situation where the body itself feels out of control.
Building the Infrastructure of Support
The presence of eight METAvivor board members at the Philadelphia conference—hailing from states as diverse as Massachusetts, Florida, California, and New Jersey—demonstrated the organization’s decentralized yet unified strength.
The conference also served as a recruitment hub. Through the efforts of volunteers like Tim Bigelow, who managed the METAvivor booth, the organization successfully engaged attendees in the "peer-to-peer" leadership model. This model is essential for the sustainability of the MBC community. By training survivors to lead local support groups, METAvivor ensures that the emotional support necessary to navigate a terminal diagnosis is accessible at the local level, far beyond the reach of annual conferences.
Data and Hope: The Clinical Trial Saga
While the advocacy work is vital, the personal stakes remain high. Dr. Shanahan’s public transparency regarding her own clinical trial provides a rare, transparent look at the "saga" of terminal care.
In the world of oncology, "stability" is often the goal, but "improvement" is the dream. After months of anticipation, the latest scan results have provided a rare moment of optimism: after only two months on her current trial regimen, every one of her numerous metastases has shown decreased activity.
This update serves as a powerful reminder of the "why" behind the advocacy. Every policy change, every grant reviewed, and every awareness campaign led by METAvivor is designed to bring these types of positive clinical outcomes to a broader segment of the MBC population. The hope is that through continued research, the "miracle" of a successful trial will eventually become a standard medical reality.
Looking Forward: How to Get Involved
The momentum generated at the Philadelphia conference is expected to carry into the next fiscal year for METAvivor. As Dr. Shanahan emphasizes, the organization’s strength lies in its volunteers. Whether through the professional review of research grants or the emotional labor of peer support, there are numerous avenues for contribution.
For those interested in the ongoing fight against metastatic breast cancer, the organization’s "Take Action" portal serves as the primary gateway for engagement.
Key Areas for Potential Volunteers:
- Grant Reviewing: Providing a patient perspective on the scientific merit and impact of research proposals.
- Peer-to-Peer Leadership: Undergoing training to facilitate support groups in local communities.
- Advocacy Awareness: Leveraging social and professional networks to amplify the need for dedicated metastatic breast cancer funding.
Conclusion
The recent activities of METAvivor’s leadership represent the vital synthesis of modern medicine and human connection. By balancing the clinical realities of survival with the organizational demands of non-profit leadership, Dr. Kelly Shanahan and her colleagues are redefining what it means to live with metastatic breast cancer. As they continue to push for progress, the message remains clear: the fight against MBC is not just a scientific endeavor; it is a human one that requires the engagement, empathy, and persistent action of the entire community.
For more information on METAvivor’s ongoing initiatives, please visit metavivor.org.
About the Author
